Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 905

2.

Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.

Kuritzkes DR, Marschner I, Johnson VA, Bassett R, Eron JJ, Fischl MA, Murphy RL, Fife K, Maenza J, Rosandich ME, Bell D, Wood K, Sommadossi JP, Pettinelli C.

AIDS. 1999 Apr 16;13(6):685-94.

PMID:
10397563
4.
5.

An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.

Foudraine NA, de Jong JJ, Jan Weverling G, van Benthem BH, Maas J, Keet IP, Jurriaans S, Roos MT, Vandermeulen K, de Wolf F, Lange JM.

AIDS. 1998 Aug 20;12(12):1513-9.

PMID:
9727573
6.
7.

A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).

Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, Yangco B, Marlowe SI, Wright D, Cohen C, Cooley T, Mauney J, Uffelman K, Schoellkopf N, Grosso R, Stevens M.

AIDS. 2000 Jul 28;14(11):1591-600.

PMID:
10983646
8.

A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).

Eron JJ Jr, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R, Stevens M.

AIDS. 2000 Jul 28;14(11):1601-10.

PMID:
10983647
9.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
10.

A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.

McKinney RE Jr, Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ, Brouwers P, Mitchell WG, Yogev R, Wara DW, Wiznia A, Mofenson L, McNamara J, Spector SA.

J Pediatr. 1998 Oct;133(4):500-8.

PMID:
9787687
11.

Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.

Vidal C, García F, Gatell JM, Leal M, Clotet B, Pumarola T, Miró JM, Mallolas J, Ruiz L, Cruceta A, Tortajada C.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Sep 1;19(1):55-60.

PMID:
9732070
12.

Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511).

Saag MS, Tebas P, Sension M, Conant M, Myers R, Chapman SK, Anderson R, Clendeninn N; Virqacept Collaborative Study Group.

AIDS. 2001 Oct 19;15(15):1971-8.

PMID:
11600825
13.

A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.

Haubrich R, Thompson M, Schooley R, Lang W, Stein A, Sereni D, van der Ende ME, Antunes F, Richman D, Pagano G, Kahl L, Fetter A, Brown DJ, Clumeck N.

AIDS. 1999 Dec 3;13(17):2411-20.

PMID:
10597783
18.

A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.

Sáez-Llorens X, Nelson RP Jr, Emmanuel P, Wiznia A, Mitchell C, Church JA, Sleasman J, Van Dyke R, Richardson CG, Cutrell A, Spreen W, Hetherington S.

Pediatrics. 2001 Jan;107(1):E4.

PMID:
11134468
19.
20.

Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.

Eron JJ, Yetzer ES, Ruane PJ, Becker S, Sawyer GA, Fisher RL, Tolson JM, Shaefer MS.

AIDS. 2000 Apr 14;14(6):671-81. Erratum in: AIDS 2000 Jun 16;14(9):1295.

PMID:
10807190
Items per page

Supplemental Content

Write to the Help Desk